<SEC-DOCUMENT>0001193125-22-138700.txt : 20220503
<SEC-HEADER>0001193125-22-138700.hdr.sgml : 20220503
<ACCEPTANCE-DATETIME>20220503161614
ACCESSION NUMBER:		0001193125-22-138700
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220503
DATE AS OF CHANGE:		20220503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celularity Inc
		CENTRAL INDEX KEY:			0001752828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831702591
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258600
		FILM NUMBER:		22887096

	BUSINESS ADDRESS:	
		STREET 1:		170 PARK AVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		609-235-1010

	MAIL ADDRESS:	
		STREET 1:		170 PARK AVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GX Acquisition Corp.
		DATE OF NAME CHANGE:	20180912
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d353086d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT No.&nbsp;1</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated April&nbsp;7, 2022)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-258600</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g353086g0503110618887.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 22,874,999 Shares of Class&nbsp;A Common Stock Issuable Upon Exercise of Warrants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 129,858,855 Shares of Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 8,499,999 Warrants to Purchase Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus, dated April&nbsp;7, 2022 (the &#147;Prospectus&#148;), which forms a part of our
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-258600).</FONT> This prospectus supplement is being filed to update and supplement the information in the Prospectus with the
information contained in our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on May&nbsp;3, 2022 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report
to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus and this prospectus supplement relate to the issuance by us of an aggregate of up to
22,874,999 shares of our Class&nbsp;A common stock, $0.0001 par value per share (the &#147;Class&nbsp;A Common Stock&#148;), which consists of (i)&nbsp;the issuance by us and resale of up to 8,499,999 shares of Class&nbsp;A Common Stock that are
issuable upon the exercise of (A) 7,000,000 warrants issued in a private placement to GX Sponsor LLC (the &#147;Sponsor&#148;), in connection with the GX IPO and (B) 1,499,999 warrants issued to certain members of the Sponsor as repayment for
certain working capital loans made to GX (the warrants in (A)&nbsp;and (B) collectively, the &#147;Private Placement Warrants&#148;), and (ii)&nbsp;up to 14,375,000 shares of Class&nbsp;A Common Stock that are issuable upon the exercise of
14,375,000 warrants (the &#147;Public Warrants,&#148; and, together with the Private Placement Warrants, the &#147;Warrants&#148;) issued in the GX IPO. We will receive the proceeds from the exercise of any Warrants for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus and this prospectus supplement also relates to the offer and sale from time to time by the selling securityholders named in the
Prospectus or their permitted transferees (the &#147;selling securityholders&#148;) of (i)&nbsp;up to 129,858,855 shares of Class&nbsp;A Common Stock consisting of (a)&nbsp;up to 8,340,000 shares of Class&nbsp;A Common Stock issued in a private
placement pursuant to subscription agreements (&#147;Subscription Agreements&#148;) entered into on January&nbsp;8, 2021 (b) up to 2,000,000 shares of Class&nbsp;A Common Stock issued in a private placement pursuant to a subscription agreement
entered into on May&nbsp;5, 2021 with Palantir Technologies Inc. (&#147;Palantir Technologies&#148;), (c) up to 976,943 shares of Class&nbsp;A Common Stock issued in private placements on July&nbsp;21, 2021 to certain advisors of Legacy Celularity
and GX, (d)&nbsp;up to 7,187,500 shares of Class&nbsp;A Common Stock previously held by the Sponsor following a private placement in connection with the initial public offering of GX, (e)&nbsp;up to 8,499,999 shares of Class&nbsp;A Common Stock
issuable upon exercise of the Private Placement Warrants, (f)&nbsp;up to 19,811,204 shares of Class&nbsp;A Common Stock issuable upon exercise of the Converted Legacy Warrants, (g)&nbsp;up to 11,744,882 shares of Class&nbsp;A Common Stock issuable
upon exercise of options and awards and (h)&nbsp;up to 71,298,327 shares of Class&nbsp;A Common Stock pursuant to that certain Registration Rights Agreement (the &#147;Registration Rights Agreement&#148;), dated July&nbsp;16, 2021, between us and
certain selling securityholders granting such holders registration rights with respect to such shares, and (ii)&nbsp;up to 8,499,999 Private Placement Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A Common Stock and Public Warrants are listed on The Nasdaq Stock Market LLC under the symbols &#147;CELU&#148; and
&#147;CELUW&#148;, respectively. On May&nbsp;2, 2022, the last reported sales price of Class&nbsp;A Common Stock was $11.64 per share and the last reported sales price of our Public Warrants was $1.47 per warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements thereto, which is to be
delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and
supersedes the information contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is not complete without, and may not be delivered or utilized
except in connection with, the Prospectus, including any amendments or supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a
high degree of risk. You should review carefully the risks and uncertainties described in the section titled &#147;</B><B><I>Risk Factors</I></B><B>&#148; beginning on page 15 of the Prospectus, and under similar headings in any amendments or
supplements to the Prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities, or passed upon the accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prospectus supplement dated May&nbsp;3, 2022. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;3, 2022 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CELULARITY INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38914</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-1702591</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File&nbsp;Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>170 Park Ave,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Florham Park, NJ</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>07932</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (908)
<FONT STYLE="white-space:nowrap">768-2170</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Class&nbsp;A Common Stock, $0.0001 par value per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CELU</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Warrants, each exercisable for one share of Class&nbsp;A Common Stock at an exercise price of $11.50 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CELUW</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp; &#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.
&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first quarter of 2022, Celularity Inc. (the &#147;Company&#148;) submitted an Investigational New Drug Application (&#147;IND&#148;) to investigate <FONT
STYLE="white-space:nowrap">CYCART-19</FONT> for treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. On April&nbsp;29, 2022, the Company received an <FONT STYLE="white-space:nowrap">e-mail</FONT> notification from the United
States Food and Drug Administration (the &#147;FDA&#148;) that it will be seeking additional information before the Company can proceed with the planned Phase 1/2 clinical trial.&nbsp;The Company expects to receive formal written communication with
additional information from the FDA by late May and plans to work with the FDA in an effort to resolve its questions as promptly as possible.&nbsp;Accordingly, the Company expects to commence the trial in the second half of 2022, assuming clearance
of the IND. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cautionary Notice Regarding&nbsp;Forward-Looking&nbsp;Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various statements in this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> concerning the Company&#146;s future expectations, plans and
prospects, including without limitation, the Company&#146;s expectations with respect to the timing of the planned Phase 1/2 clinical trial, may constitute&nbsp;forward-looking&nbsp;statements for the purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995 and other federal securities laws. Although the Company believes that the expectations reflected in the&nbsp;forward-looking&nbsp;statements are reasonable, the Company cannot guarantee such outcomes.
The forward-looking statements included in this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> are subject to a number of risks, uncertainties and assumptions, including, without limitation, the expected timing of review by
governmental authorities. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> As a result, you are cautioned not to rely on
these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;3, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CELULARITY INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Keary Dunn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Keary Dunn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g353086g0503110618887.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g353086g0503110618887.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ *$# 2(  A$! Q$!_\0
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M'S')?#[PWJ?AO2Y(-1NE<2-N2W3D0GOS[^E=B12T5Y\I.3NR3G_$OA:T\00
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M[U>[TN&0F[M%5ID*D;0W3GO2LP+SRQQ#,CJ@)P"QP,T[-<3\40?^$8MO^O\
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<<29'*H3\J_U_&NT'2JK23E9;?U<84445D(__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
